Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650774 | 0.94 | ABCB1 (0.35) | GPR35MTNR1AMTNR1BABCB1NSD2 | |
| SCHEMBL26144386 | 0.83 | CETP (0.38) | ABCB1MAPTUSP2CETPAR | |
| SCHEMBL23201206 | 0.78 | ABCB1 (0.39) | ABCB1MAPTUSP2ALDH1A1CETP | |
| SCHEMBL6791097 | 0.77 | PRSS1 (0.39) | MTNR1AMTNR1BMEN1ALDH1A1KMT2A | |
| SCHEMBL6790938 | 0.75 | RECQL (0.39) | MTNR1AMTNR1BMAPTMEN1GAA | |
| SCHEMBL1009189 | 0.74 | NSD2 (0.45) | ABCB1NSD2MEN1KMT2A | |
| SCHEMBL5987415 | 0.73 | ABCB1 (0.34) | ABCB1 | |
| SCHEMBL1010216 | 0.73 | MEP1A (0.50) | ABCB1 | |
| SCHEMBL379928 | 0.71 | CACNA1G (0.37) | GPR35ABCB1NSD2ALDH1A1CETP | |
| SCHEMBL28847028 | 0.71 | ABCB1 (0.38) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448534-A1 | 6-MEMBERED UNSATURATED HETEROCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OFTHE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2003029224-A1 | 6-MEMBERED UNSATURATED HETEROCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, TFPI2 | GPR35 3496/4885MTNR1A 3871/4885MTNR1B 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.